Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADG106 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| ADG106 Dose escalation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ADG106 | DRUG | IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment. |
Inclusion Criteria: 1. Male or female, 18 years to 75 years of age at the time of consent. 2. Provide written informed consent. 3. Subjects with advanced and/or metastatic histologically or cytologically confirmed solid tumor and/or non-Hodgkin lymphoma who are refractory or relapsed from standard ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ADG106 is an investigational small molecule developed by Adagene Inc. for advanced or metastatic solid tumors and non-Hodgkin lymphoma. It is designed as a CD137 agonist and has been studied in Phase 1 clinical trials in China and the United States. It is not an approved therapy.
ADG106 targets CD137, a protein also known as 4-1BB. CD137 is a co-stimulatory receptor on immune cells, and ADG106 is described as a CD137 agonist, meaning it is designed to activate this receptor. The mechanism is intended to stimulate immune responses against tumors.
ADG106 is being developed by Adagene Inc., a biotechnology company that trades under the ticker ADAG. Adagene sponsored the Phase 1 studies of ADG106 in advanced or metastatic solid tumors and non-Hodgkin lymphoma.
ADG106 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The completed Phase 1 studies evaluated ADG106 in patients with advanced or metastatic solid tumors and non-Hodgkin lymphoma.
ADG106 has been evaluated in two completed Phase 1 trials. NCT03802955 studied ADG106 in advanced or metastatic solid tumors and non-Hodgkin lymphoma in China with 62 participants. NCT03707093 studied the CD137 agonist ADG106 in the same conditions in the United States with 49 participants.
ADG106 is being studied for the treatment of advanced or metastatic solid tumors and non-Hodgkin lymphoma. Both completed Phase 1 trials enrolled adults aged 18 years and older with these conditions. It remains an investigational agent and is not approved for any use.